Viatris Inc.
VTRS Healthcare Drug Manufacturers - Specialty & Generic NASDAQ
$14.75
+$0.23 (+1.58%)
Open: $14.69 | High: $14.78 | Low: $14.48 | Prev Close: Prev Close: $14.52
Market Cap: $17.18B
Volume: 10.1M | Avg: 10.3M
Last updated: April 24, 2026 at 02:05 AMInvestment Rating
Sell
Overall Score: 40/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 440
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | -4.92 |
| P/B Ratio | 1.16 |
| P/S Ratio | 1.20 |
| EPS | $-3.00 |
| Beta | 0.82 |
| Shares Outstanding | 1.16B |
| 52-Week High | $16.47 |
| 52-Week Low | $7.82 |
| SMA 50 | $14.37 |
| SMA 200 | $11.69 |
| Dividend Yield | 3.25% |
| Annual Dividend | $0.48 |
| Next Earnings | May 07, 2026 12:30 PM ET |
Financial Ratios
| Gross Margin | 35.1% |
| Operating Margin | -18.6% |
| Net Margin | -24.6% |
| ROE | -23.0% |
| ROA | -9.5% |
| Debt/Equity | 1.00 |
| Current Ratio | 1.30 |
| Quick Ratio | 0.74 |
Balance Sheet
| Total Assets | $37.19B |
| Total Liabilities | $22.48B |
| Total Equity | $14.71B |
|
|
|
| Cash | $1.35B |
| Total Debt | $14.70B |
| Net Debt | $13.35B |
Income Statement
| Revenue | $14.30B |
| Gross Profit | $5.01B |
| Operating Income | $-2,663,100,000 |
| Net Income | $-3,514,900,000 |
|
|
|
| EBITDA | $-395,400,000 |
| Revenue/Share | $12.41 |
Cash Flow
| Operating CF | $2.32B |
| CapEx | $378.80M |
| Free Cash Flow | $1.94B |
|
|
|
| Book Value/Share | $12.76 |
| Tangible Book/Share | $-6.20 |
| Equity/Share | $12.76 |
Technical Indicators
| RSI (14) | 63.24 Neutral |
| MACD |
0.20
Signal: 0.04
|
| Volatility | 33.32% |
| Trading Signal | Bullish |
Performance & Returns
| 1 Year | +60.33% |
| Sharpe Ratio | 1.81 Good |
| Volatility (Ann.) | 32.1% Moderate |
| VTRS (1Y) | +60.33% |
| S&P 500 (1Y) | +14.41% |
| Alpha (Excess Return) | +45.92% |
Sector Comparison (Healthcare)
| Metric | VTRS | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | -4.92 | 26.87 | 4% |
| P/B Ratio | 1.16 | -21.04 | 12% |
| ROE (%) | -22.99% | -9.42% | 14% |
| Net Margin (%) | -24.58% | 10.14% | 2% |
| Stock Score | 440 | 551.0 | 8% |
| 1Y Return (%) | +60.33 % | +3.99 % | 100% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VTRS | $14.75 | $14.76 | $14.42 | $14.07 | $14.42 | $11.70 | 63.24 | 0.20 | 33.32% | 430908 | Neutral | Bullish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the VTRS stock
News Sentiment
| Ticker | Headline | Sentiment | Source | URL |
|---|---|---|---|---|
| VTRS | Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 | Neutral | prnewswire.com | Read More |
| VTRS | Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting | Neutral | prnewswire.com | Read More |
| VTRS | Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines Transcript | Positive | seekingalpha.com | Read More |
| VTRS | Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) | Neutral | prnewswire.com | Read More |
| VTRS | Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 | Positive | prnewswire.com | Read More |
Recent Insider Trading
No recent insider trading data available for VTRS
Company Information
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
| CEO | Scott Andrew Smith |
| Employees | 32000 |
| Country | US |
| IPO Date | 1980-03-17 |
| Exchange | NASDAQ |
| Website | https://www.viatris.com |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category